Hepatology(Liver, Pancreatic, Gall Bladder)

  • Home
  • Hepatology(Liver, Pancreatic, Gall Bladder)
Headache Relief Shampoo Voted #1 Best New Product in 2019

headache relief shampoo bottles

Dr. D’s Medicated Headache Relief Shampoo is now available. This medicated shampoo will help alleviate headaches simply by soaking it on your head. Finding relief from minor to severe headaches shouldn’t always involve reaching for a bottle of pills. Dr. D is here to give you another option. Our proprietary formula will leave your head feeling better.

BUY NOW! http://headachereliefshampoo.com/product/headache-relief-shampoo/

January 1, 2019Comments OffHeadache Drug Trial | Headache Relief | Headache Shampoo | Headache Study | Headache Therapy
Bile Composition in Healthy and Gallstones Patients

Conditions:   Cholelithiasis;   Gall Stone;   Gall Bladder Disease
Interventions:   Diagnostic Test: Bile test;   Diagnostic Test: Blood test;   Diagnostic Test: Gall stone study;   Diagnostic Test: Microbiological bile test
Sponsor:   Hospital Son Espases
Not yet recruiting
ClinicalTrials.gov: Gall Bladder | Recruiting, Not yet recruiting, Available Studies | First posted in the last 100 days

June 10, 2019Comments OffBile | Composition | Gallstones | Healthy | Patients
Nivolumab in Combination With Chemotherapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Conditions:   Borderline Resectable Pancreatic Adenocarcinoma;   Resectable Pancreatic Ductal Adenocarcinoma
Interventions:   Drug: Fluorouracil;   Drug: Irinotecan;   Drug: Irinotecan Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Biological: Nivolumab;   Drug: Oxaliplatin;   Procedure: Therapeutic Conventional Surgery
Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 9, 2019Comments OffBefore | Borderline | Cancer | Chemotherapy | Combination | Nivolumab | Pancreatic | Patients | Resectable | Surgery | Treating
Effects of Low Fat Versus Low Carbohydrate Diets on Energy Metabolism

Conditions:   Healthy;   Healthy Volunteers
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 8, 2019Comments OffCarbohydrate | Diets | Effects | Energy | Metabolism | Versus
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer

Conditions:   Pancreatic Ductal Adenocarcinoma (PDAC);   Cancer of Pancreas;   Pancreatic Cancer, Adult;   Pancreas Adenocarcinoma;   Pancreatic Neoplasms;   Pancreatic Cancer Non-resectable;   Pancreatic Cancer Resectable
Interventions:   Drug: Oxaliplatin;   Drug: Leucovorin;   Drug: Irinotecan Hydrochloride;   Drug: 5-FU
Sponsor:   UNC Lineberger Comprehensive Cancer Center
Not yet recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 7, 2019Comments OffCancer | FOLFIRINOX | Nonmetastatic | Pancreatic | Subjects | Subtypes | Tumor
The Effect of Glucagon on Rates of Hepatic Mitochondrial Oxidation in Man Assessed by PINTA

Condition:   Healthy Participants
Intervention:   Drug: Glucagon
Sponsors:   Yale University;   Merck Sharp & Dohme Corp.
Recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 6, 2019Comments OffAssessed | Effect | Glucagon | Hepatic | Mitochondrial | Oxidation | PINTA | Rates
ALTA TIPS: A 5-year Longitudinal Observational Study of Patients With Cirrhosis Undergoing TIPS Placement

Conditions:   Cirrhosis, Liver;   Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Intervention:  
Sponsors:   Northwestern University;   University of California, San Francisco;   Scripps Health;   University of Wisconsin, Madison;   University of Florida;   University of Arizona;   Stanford University;   Columbia University;   Weill Medical College of Cornell University;   Baylor Scott and White Health;   Mayo Clinic
Not yet recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 5, 2019Comments Off5year | ALTA | Cirrhosis | Longitudinal | Observational | Patients | Placement | Study | TIPS | Undergoing
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Gemcitabine and Nab-paclitaxel) in Locally Advanced Pancreatic Cancer

Condition:   Pancreatic Cancer Non-resectable
Interventions:   Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel;   Drug: Placebo + Gemcitabine + Nab-paclitaxel
Sponsor:   FibroGen
Recruiting
ClinicalTrials.gov: Pancreatic | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 4, 2019Comments OffAdvanced | Cancer | Chemotherapy | Combination | Efficacy | Evaluation | Gemcitabine | Locally | Nabpaclitaxel. | NEOADJUVANT | Pamrevlumab | Pancreatic | Safety | Treatment
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer

Conditions:   Cancer of the Prostate;   Castration-resistant Prostate Cancer
Intervention:   Drug: Gadoxetate Sodium
Sponsor:   University of Cincinnati
Recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 3, 2019Comments OffAggressive | Biomarker | Cancer | Enhanced | Gadoxetate | Prostate | Sodium
Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

Conditions:   Hepatic Impairment;   Healthy Participants
Intervention:   Drug: Linzagolix
Sponsor:   ObsEva SA
Recruiting
ClinicalTrials.gov: Liver | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 2, 2019Comments OffFemale | Function | Hepatic | Impaired | Linzagolix | Normal | Pharmacokinetics | Safety | Study | Subjects